作者：
Arkenau, Hendrik-Tobias [1]
;
Martin-Liberal, Juan [2]
;
Calvo, Emiliano [3]
;
Penel, Nicolas [4]
;
Krebs, Matthew G. [5]
;
Herbst, Roy S. [6]
;
Walgren, Richard A. [7]
;
Widau, Ryan C. [8]
;
Mi, Gu [9]
;
Jin, Jin ;
Ferry, David ;
Chau, Ian
作者单位：
Vall dHebron Inst Oncol, Barcelona, Spain
[1]
Eli Lilly & Co, New York, NY USA
[2]
Ctr Integral Oncol Clara Campal, START Madrid HM CIOCC, Early Clin Drug Dev Program, Madrid, Spain
[3]
Ctr Oscar Lambret, Lille, France
[4]
Royal Marsden Hosp, Sutton, Surrey, England
[5]
Christie NHS Fdn Trust, Manchester, Lancs, England
[6]
Eli Lilly & Co, Indianapolis, IN 46285 USA
[7]
Yale Univ, Yale Canc Ctr, Sch Med, New Haven, CT USA
[8]
Sarah Cannon Res Inst UK, Drug Dev Unit, 93 Harley St, London W1G 6AD, England
[9]
发布时间
2019-04-18
换一批
